Acute Myeloid Leukemia Study
CALGB 10502: Dose Escalation and Phase II Study of Bortezomib Added to Standard Danunoriubicin and Cytarabine Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60-75 years
Protocol ID
08-255
Protocol Description
The purpose of this study is to test the safety and effectiveness of the addition of the experimental drug bortezomib to a treatment regimen for patients with acute myeloid leukemia (AML), and to see the effects (good and bad) of bortezomib.
Eligibility Criteria
Patients with acute myeloid leukemia (AML)
Primary Investigator(s)
- Jonathan Kolitz, MD